![]() (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine in more than 10,000 individuals 16 years of age and older. NEW YORK & MAINZ, Germany-(BUSINESS WIRE). ![]() Companies plan to submit these data to FDA, EMA and other regulatory agencies to further support licensure in the U.S.In trial with more than 10,000 participants 16 years of age and older, COVID-19 booster was found to have a favorable safety profile.First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against disease during a period when Delta was the prevalent strain.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |